Overview

New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia

Status:
Withdrawn
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The safety and efficacy of combining NRX 195183 with arsenic trioxide in treating untreated APL will be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
University of Southern California
Collaborator:
Sponsor Name Pending
Treatments:
Arsenic Trioxide